Day: October 26, 2025
Ad hoc announcement pursuant to Art. 53 LRTransaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases
Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipeline
Expected to unlock multi-billion-dollar opportunities with planned product launches before 2030
Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, and bolsters mid-single digit long-term growth
As part of the agreement, Avidity will separate its early-stage precision cardiology programs into a new company (“SpinCo”) prior to closing
Consideration totals USD 12bn in cash; closing expected in H1 2026 subject to completion of the separation of SpinCo from Avidity and other...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Written by Customer Service on . Posted in Public Companies.
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy
Favorable safety profile with no dose-limiting toxicities supports plan to enable same-day discharge post FT819 treatment broadening patient accessibility
All patients surpassing a 3-month post-treatment time point (n=5) showed significant reductions in the SLE Disease Activity Index (SLEDAI-2K) score and Physician’s Global Assessment (PGA)
SLE patients with lupus nephritis (LN) surpassing a 3-month post-treatment time point (n=2) achieved complete renal response (CRR) at 6 months; first patient continues in drug-free Definition of Remission in SLE (DORIS) at 15 months follow-up
Cumulative clinical dataset provides...
Village Farms International to Report Q3 2025 Results on November 10, 2025
Written by Customer Service on . Posted in Public Companies.
Management to Host Conference Call November 10 at 8:30 a.m. ET
VANCOUVER, British Columbia, Oct. 26, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced it will host a conference call to discuss its third quarter 2025 financial results on Monday, November 10, 2025, at 8:30 a.m. ET. Participants can access the conference call via a webcast at Village Farms Third Quarter 2025 Conference Call Webcast or on the Company website at Village Farms – Events. Participants wanting to access the conference call by telephone must register in advance at Village Farms Third Quarter 2025 Conference Call Registration to receive telephone dial-in information.
The live question and answer session will be limited to analysts; however, others are invited to submit questions...
HD Hyundai Heavy Industries and HII Execute Memorandum of Agreement to Collaborate on Distributed Shipbuilding and Pursue Teaming on Auxiliary and Commercial Vessels
Written by Customer Service on . Posted in Public Companies.
GYEONGJU, South Korea, Oct. 26, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) and HD Hyundai Heavy Industries (HHI), two of the world’s leading shipbuilders, signed a memorandum of agreement (MOA) today at the Asia-Pacific Economic Cooperation (APEC) 2025 forum to advance the objectives of the shipbuilding dialogue between the United States and Republic of Korea. The signing event was attended by Joo Won-ho, president of the Naval & Special Ship Business Unit at HHI, and Eric Chewning, HII’s executive vice president of maritime systems and corporate strategy.
“This marks the beginning of deeper collaboration between not only our companies, but each of our countries, that will support enduring changes to military and commercial shipbuilding in America,” Chewning said. “We look forward to working collaboratively with HHI, the U.S....
